Drugs / FT1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06610487 | Aug 2024 → Aug 2025 | diarrheal disease | Chongqing Peg-Bio Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07704047 | Aug 2026 → Apr 2027 expected | BD syndrome, short bowel syndrome | Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07704047 ↗ |
| Modality | Peptide | “Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1)” NCT07704047 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT06610487 ↗ |